Informa Stock News

The 2022 edition of LEAP has set a new record to be the debut technology event having more than 100,000 registered attendees from more than 80 countries. LEAP conference is a unique event that brings together great minds from technology Corporations, pioneers from global start-ups and venture capitalists with the aim of accelerating economic growth. According to report, Over 700 exhibitors including the worlds leading technology companies and over 1,500 of the most innovative start-ups, along with more than 500 international speakers took part in LEAP22 which was held in Riyadh, making it the largest ever first edition for a technology event. LEAP22 saw more than $6.4 billion of investments and new technology initiatives announced, with US$1 million in prizes awarded to the winners of the Rocket Fuel Start-up Competition, an international contest to find the best new business ideas, the report said. However, the conference saw the announcement of multiple investments and funds for start-ups and entrepreneurs of over $266 million and among the announcement was the completion of closing of the second round of Khwarizmi Ventures fund with a value of $69.8 million, investment into the Emkan VC fund of over $49.8 million and the launch by Saudi Venture Investment Company of the Investment in Advanced Stage Funds, with a value of over $134 million, to promote the growth of start-ups.

Events organiser Informa said on Thursday that it has agreed to sell its pharma intelligence business to US investment firm Warburg Pincus for £1.9bn, as it announced a share buyback.

LONDON , Feb. 10, 2022 /CNW/ -- Warburg Pincus, a leading global growth investor, today announced the acquisition of Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa PLC (LSE:INF.L), the international B2B markets knowledge services and business intelligence group. Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment. The investors plan to extend the company''s leading position in the pharmaceutical data and analytics market, investing in the creation of innovative products for its customers. Informa will retain 15% ownership in the company. Pharma Intelligence is a leading operator in the $22 billion global pharma and life sciences analytics markets. The company holds the leading position in the clinical trial intelligence space, providing insights on patient enrollment and demographics, trial progress, individual trial sites and investigators for more than 375,000 clinical trials across 180 countries.

Informa plc (LON:INF) insider David Flaschen bought 10,000 shares of the firms stock in a transaction dated Thursday, December 16th. The shares were acquired at an average price of GBX 489 ($6.46) per share, for a total transaction of £48,900 ($64,622.70). LON:INF opened at GBX 502 ($6.63) on Friday. The companys 50-day moving average price []

Informa plc (LON:INF) insider David Flaschen acquired 10,000 shares of Informa stock in a transaction that occurred on Thursday, December 16th. The stock was acquired at an average price of GBX 489 ($6.46) per share, with a total value of £48,900 ($64,622.70). LON:INF traded up GBX 15.20 ($0.20) on Friday, hitting GBX 501.20 ($6.62). The […]

Powerful AppCrown technology makes integration seamless, without code, no manual input and within 24 hours Zephyr, a subsidiary of Informa plc, and a recognized leader in providing data, insight and analysis to investment professionals and financial advisors via their Zephyr financial services platform, has partnered with AppCrown, making it possible to fully connect Salesforce Financial [] The post Informas Zephyr Announces Salesforce Cloud Integration Via AppCrown appeared first on SalesTech Star .

Citigroup reissued their buy rating on shares of Informa (LON:INF) in a research report released on Wednesday morning, Analyst Ratings Network reports. The firm currently has a GBX 725 ($9.61) price objective on the stock. Several other brokerages also recently issued reports on INF. JPMorgan Chase & Co. upped their price objective on Informa from [] The post Informa (LON:INF) Earns Buy Rating from Citigroup appeared first on ETF Daily News .

Informa (LON:INF)s stock had its buy rating reissued by research analysts at Citigroup in a report issued on Wednesday, PriceTargets.com reports. They currently have a GBX 725 ($9.61) price objective on the stock. Citigroups target price would suggest a potential upside of 43.22% from the companys current price. A number of other analysts have also []

Informa surges jumped as much as 6.9 per cent today after a fresh growth strategy the promise of a bumper payout cheered investors.

NEW YORK, Dec. 7, 2021 /PRNewswire/ -- Informa PLC (LSE: INF.L), the international B2B markets, knowledge services and business intelligence group, has acquired NetLine Corporation, which brings established capabilities in audience development and B2B digital demand generation.

(Reuters) Events organiser Informa said on Tuesday it plans to return 1 billion pounds ($1.32 billion) to shareholders through stock buyback and a special dividend next year and aims to exceed pre-pandemic revenue by 2024, sending its shares up 7.4%.

New Informa: Accelerated growth and portfolio focus

Advance Market Analytics published a new research publication on "Exhibition Organizing Market Insights, to 2026" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities

Berenberg Bank reissued their buy rating on shares of Informa (LON:INF) in a research report report published on Wednesday morning, PriceTargets.com reports. The brokerage currently has a GBX 640 ($8.36) target price on the stock. Several other analysts also recently commented on INF. Shore Capital reaffirmed a hold rating on shares of Informa in a […]

Credit Suisse Group reiterated their outperform rating on shares of Informa (OTCMKTS:IFJPY) in a report published on Thursday, The Fly reports. A number of other analysts also recently weighed in on the stock. Barclays reiterated an overweight rating on shares of Informa in a research report on Friday, October 8th. JPMorgan Chase & Co. reissued []